Rebound Hyperglycemia Does Not Directly Cause Cardiac Arrest
Rebound hyperglycemia itself does not precipitate cardiac arrest. The available evidence shows that while hyperglycemia is associated with poor cardiovascular outcomes in specific contexts (like acute myocardial infarction), the transient glucose elevation following hypoglycemia correction does not independently trigger cardiac arrest.
Key Evidence Analysis
What the Research Actually Shows
The most relevant study directly addressing your question found that proteomic cardiovascular biomarkers showed no changes following rebound hyperglycemia (glucose rising from 1.8 to 12.2 mmol/L after severe hypoglycemia) 1. Any cardiovascular risk changes observed were attributable to the hypoglycemia itself, not the subsequent glucose fluctuation. This 2024 study specifically examined whether rebound hyperglycemia increases cardiovascular risk and found it does not.
The Real Culprits in Cardiac Arrest
The evidence points to different mechanisms:
- Hypoglycemia itself poses cardiovascular risk, not the rebound 1
- Rebound hyperkalaemia (not hyperglycemia) after glucose-insulin-potassium infusion discontinuation has caused cardiac arrest 2. This is a critical distinction—the electrolyte disturbance, not the glucose elevation, was the lethal factor
- Baseline hyperglycemia in acute coronary syndromes is associated with increased mortality and adverse events 3, but this reflects stress hyperglycemia in the context of acute cardiac injury, not rebound phenomena
Clinical Context Matters
Current guidelines recommend glucose targets of 6.0-10.0 mmol/L (108-180 mg/dL) for inpatients, with acceptable ranges up to 12.0 mmol/L (216 mg/dL) 4. These ranges acknowledge that:
- Intensive glucose lowering has not shown additional benefit and may increase hypoglycemia risk 4
- The risk comes from sustained hyperglycemia in critically ill patients, not transient elevations
- Hypoglycemia avoidance is more critical than aggressive glucose control in most hospitalized patients
Important Caveats
Monitor potassium closely when using insulin infusions—hypokalaemia occurs in ~50% of hyperglycemic crisis treatments, and severe hypokalaemia (<2.5 mEq/L) is associated with increased mortality 4. The cardiac arrest case report involved rebound hyperkalaemia, emphasizing electrolyte management over glucose fluctuations 2.
In diabetic patients specifically, both extremes matter: very low systolic blood pressure (<100 mmHg) and hypertension increase sudden cardiac arrest risk 5, but this relates to chronic hemodynamic status, not acute glucose changes.